CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) — Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent and highly selective oral KIT inhibitor for the treatment of severe allergies and inflammation, today announced the appointment from Julie Person to the administrative director. Ms. Person brings more than 20 years of experience building biopharmaceutical organizations that align people’s practices with strategy to drive positive outcomes for patients and teams. In her role, Ms. Person will assume leadership responsibilities for human resources, corporate communications and facilities.
“I am thrilled to welcome Julie to the team to lead our efforts around organizational development as Third Harmonic evolves and our work progresses,” said Natalie Holles, Managing Director of Third Harmonic Bio. “We are passionate about building a business that provides the infrastructure, support and growth opportunities for our team that are essential to drive peak performance as we advance THB001 for the treatment of urticaria and urticaria. ‘Other Inflammatory Diseases.’
“Behind the incredible science of Third Harmonic Bio are talented and committed employees who are dedicated to advancing the next wave of allergy and inflammation medicines,” said Ms. Person. “I look forward to working with Natalie and the rest of the leadership team to create a great culture that aligns our operating principles with our goals for the business and for THB001.”
Ms. Person joins the company from Neumora Therapeutics, where she served as Director of Human Resources and oversaw human resources and internal communications. Prior to Neumora, she was Head of Human Resources at Audentes Therapeutics and Sangamo Therapeutics, Inc. Prior to Sangamo, Ms. Person was Global Head of Talent Management at Shire Plc., where she played a key role in the integrations of Baxalta International Inc. to Shire, and Shire to Takeda Pharmaceutical Company Ltd. Prior to Shire, she spent 12 years at McKesson Corp. in various HR roles with increasing responsibilities.
Ms. Person received her undergraduate degree in communications from Saint Mary’s College in California and completed the Executive Leadership Program at the University of Michigan’s Ross School of Business.
About Third Harmonic Bio
Third Harmonic Bio is a clinical-stage biopharmaceutical company focused on advancing the next wave of allergy and inflammation medicines. The Company’s lead product candidate, THB001, is a highly selective oral small molecule inhibitor of KIT, a cell surface receptor that serves as a master regulator of mast cell function and survival. The company is participating in a Phase 1a clinical trial in healthy volunteers for THB001 and plans to initiate a Phase 1b proof-of-concept study in cold-induced urticaria in the second half of 2022. With promising properties like drug and an encouraging early clinical profile, THB001 has the potential to revolutionize the treatment of a wide range of mast cell-mediated allergic and inflammatory dermatological, respiratory and gastrointestinal diseases. Visit ThirdHarmonicBio.com or follow us on Twitter or LinkedIn to learn more about our work, our team and our culture.
Copyright 2022 GlobeNewswire, Inc.